IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS
Ibalizumab (IBA) is a long-acting humanized IgG4 monoclonal antibody that blocks HIV entry into CD4 cells while preserving normal immunological function. IBA binds to domain 2 of the CD4 receptor, away from the MHC II binding site. IBA susceptibility of patient isolates was determined at Baseline for a 24-week, Phase 3 clinical trial (TMB-301) conducted…